mesenchymal stem cell

Overview

Mesenchymal stem cell, more commonly referred to in the literature as a mesenchymal stromal cell (MSC), is a multipotent cell type studied extensively in regenerative medicine, immunology, and tissue engineering. MSCs are typically investigated for their ability to support tissue repair through paracrine signaling, immunomodulation, and interactions with the local microenvironment rather than through direct long-term engraftment alone. In recent biomedical research, MSCs have been explored as cellular therapeutics for inflammatory, ischemic, degenerative, and traumatic conditions, including myocardial infarction, stroke, diabetic kidney disease, liver injury, wound healing, and respiratory disease.

A major theme across current studies is that MSC function is strongly influenced by delivery format and microenvironmental engineering. Investigators have examined MSC-derived exosomes, secretome, and conditioned media, as well as encapsulation in hydrogels, microgels, microspheres, and bioprinted constructs to improve cell survival, retention, and sustained release of trophic factors. Mechanistically, MSC-based therapies are often linked to anti-inflammatory cytokines, VEGFA, hypoxia-inducible factor-1α, PI3K/Akt signaling, mechanistic target of rapamycin kinase, matrix metalloproteinase-9, MMP2, Prostaglandin-endoperoxide synthase 2, and B-cell-related immune effects, reflecting their broad influence on tissue repair and immune regulation.

Focus of Latest Publications

Recent publications have used mesenchymal stem cells as a therapeutic target, a cell therapy product, or a source of paracrine mediators across inflammatory, degenerative, and regenerative disease models. A recurring theme is that MSCs exert benefit largely through immunomodulatory and tissue-reparative actions rather than simple cell replacement.

Several studies focused on respiratory injury and inflammation. Exosomes derived from mesenchymal stromal cells were investigated in a murine aspiration model of lung inflammation, where they were presented as a potential therapeutic for aspiration pneumonia. In a separate phase II randomized clinical trial, umbilical cord mesenchymal stromal cells were evaluated for respiratory complications of COVID-19 infection, again emphasizing their immunomodulatory and tissue-reparative properties. Bone marrow-derived MSCs were also studied in radiation pneumonitis, where they were reported to alleviate inflammation and inhibit apoptosis through modulation of the NF-κB/NLRP3 signaling pathway.

MSC-based approaches were also examined in neurological and spinal disorders. A first-in-human case report described intraventricular administration of SHED-derived mesenchymal stem cells in neonatal post-infectious hydrocephalus, highlighting the neurotrophic and immunomodulatory properties of stem cells derived from human exfoliated deciduous teeth. In spinal cord injury, mesenchymal stem cell lysate delivered in a sustained-release nano-hydrogel was reported to reduce injury by inhibiting ferroptosis and mitochondrial intrinsic apoptosis, while platelet-rich plasma-primed bone marrow MSC-derived exosomes were shown to inhibit neuronal apoptosis and autophagy and promote nerve regeneration via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis. Another study used electroactive microneedle-augmented stem cell therapy in myocardial infarction to improve delivery and retention of MSCs at the infarct site, supporting sustained paracrine effects. In chronic stroke monkeys, MSC transplantation combined with intermittent theta-burst stimulation was associated with robust neurogenesis.

Cardiovascular and metabolic disease models were also prominent. Bioprinted dECM particle-laden microgels were used to enhance the mesenchymal stromal cell paracrine effect for myocardial infarction treatment, addressing the problem of poor survival and unstable paracrine function in the hostile infarct microenvironment. Hypoxia-preconditioned bone marrow MSCs were reported to alleviate acute liver failure in association with the VEGF/c-Met pathway, and three-dimensional aggregate culture improved the therapeutic efficacy of human umbilical cord-derived MSCs in a mouse model of metabolic dysfunction-associated steatohepatitis. A real-world evidence study also examined autologous bone marrow-derived MSC transplantation for decompensated liver cirrhosis, reporting promise in advanced cirrhosis. In diabetic kidney disease, MSCs and their secretome were reported to attenuate disease through inhibition of the mTOR-NOX4 pathway. In a related inflammatory setting, systemic MSC therapy was used in a patient with juvenile-onset rheumatoid arthritis and dialysis-dependent renal failure to reduce inflammatory burden, consistent with the immunomodulatory profile of MSCs.

Bone, cartilage, and musculoskeletal regeneration were major areas of investigation. Bone marrow MSCs were studied in age-related bone loss, where functional decline and exhaustion of BMSCs were linked to skeletal deterioration. In osteoarthritis and cartilage engineering, differentiating MSCs into healthy chondrocytes required biochemical and biomechanical stimuli, and vasoactive intestinal peptide was reported to advance chondrogenesis and modulate inflammatory and cartilage extracellular matrix-degrading mediators in human osteoarthritis articular chondrocytes. An IL-4 peptide hydrogel was shown to reprogram MSC heterogeneity toward the CD106+ population for enhanced renal repair, underscoring the importance of MSC subpopulation composition. In a three-dimensional dynamic in vitro bone remodeling model, osteoclast-MSC interactions were examined in the context of anti-osteoporotic agents. Other studies linked MSC dysfunction to diabetic bone regeneration failure, osteogenic impairment in high-glucose environments, and impaired osseointegration. Bone marrow aspirate concentrate, which is rich in MSCs, was tested for improving early osseous integration of fresh osteochondral allografts in the knee. Additional work showed that a graphene oxide-collagen scaffold enhanced MSC adhesion and proliferation while promoting osteogenic and chondrogenic differentiation and suppressing adipogenesis.

MSC-derived extracellular vesicles and secretome products were repeatedly highlighted as translational alternatives to live-cell therapy. Exosomes from bone marrow MSCs were described as promising because of their immunomodulatory and tissue repair capabilities, and magnetic graphene was used for high-performance isolation of these exosomes via Ca2+-dependent reversible recognition. Apoptotic vesicles derived from MSCs were reported to have therapeutic promise for tissue regeneration and osteoarticular disease. MSC-conditioned medium and MSC secretome were also explored in alopecia areata and other inflammatory settings, reflecting the broader interest in cell-free MSC therapeutics. In wound healing, adipose-derived MSC-loaded polysaccharide hydrogel promoted repair through angiogenesis, and CD73+ MSC transplantation improved pressure ulcer healing by promoting angiogenesis through the HIF-1α/VEGF pathway in diabetic mice.

Other studies addressed developmental, reproductive, and prenatal applications. Human umbilical cord-derived MSCs were used in a proof-of-principle study for prenatal repair of an ovine fetal myelomeningocele model. MSCs were also co-cultured with thawed human ovarian cortical tissue to improve in situ follicular activation and early development, suggesting a supportive role in reproductive tissue culture. In a macaque brain aging study, bone marrow MSCs were evaluated using 18F-FDG PET/CT imaging to assess anti-aging efficacy, indicating interest in noninvasive monitoring of MSC effects in vivo.

Across these studies, a consistent conclusion is that MSCs are being developed as versatile regenerative and immunoregulatory tools, but their clinical translation remains limited by heterogeneity, poor survival after transplantation, rapid clearance, and unstable paracrine function in diseased microenvironments. As a result, many recent strategies have focused on preconditioning, biomaterial encapsulation, aggregate culture, and secretome-based products to improve efficacy.

Key Publications

• NEWJul Effects of Mesenchymal Stem Cell-Derived Exosomes on Lung Inflammation in a Murine Aspiration Model. (The Laryngoscope, 2026, PMID 41699868): "Exosomes from mesenchymal stromal cells (MSCs) present a potential therapeutic for aspiration pneumonia."
• NEWJul Umbilical cord mesenchymal stromal cells for respiratory complications of COVID-19 infection (ProTrans): phase II randomized clinical trial. (Cytotherapy, 2026, PMID 42134096): "Mesenchymal stromal cells (MSCs), due to their immunomodulatory and tissue-reparative properties, are a potential therapeutic option."
• Jul TLR9 agonists alleviate diabetic condition by promoting the maturation of differentiated bone marrow mesenchymal stem cells in rats. (Pakistan journal of pharmaceutical sciences, 2026, PMID 42170982): "Bone marrow mesenchymal stem cells (BMSCs) can differentiate into insulin-producing cells (IPCs), but functional maturity remains limited."
• Jul A microgel bone marrow model of mesenchymal stromal cell paracrine signaling supporting hematopoietic stem cell retention. (Acta biomaterialia, 2026, PMID 42248284): "By seeding HSCs amongst mesenchymal stromal cell (MSC)-laden hydrogel microspheres (microgels), we establish paracrine-mediated interactions between HSCs and hydrogel encapsulated MSCs."
• Jul Bioprinted dECM particles-laden microgels enhance the mesenchymal stromal cell paracrine effect for myocardial infarction treatment. (Acta biomaterialia, 2026, PMID 42250666): "Mesenchymal stromal cell (MSC) transplantation represents a promising therapeutic strategy, yet its efficacy remains limited by poor survival and unstable paracrine function of transplanted cells within the hostile infarct microenvironment."
• Jun Design and integration of a novel bioreactor for articular cartilage tissue manufacturing with real-time feedback of chondrogenic gene expression. (Biofabrication, 2026, PMID 42276100): "Differentiating mesenchymal stromal cells into healthy chondrocytes for articular cartilage (AC) requires a variety of biochemical and biomechanical stimuli."
• Jun Intraventricular administration of SHED-derived mesenchymal stem cells in neonatal post- infectious hydrocephalus: a first-in-human case report. (Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026, PMID 42362959): "Mesenchymal stem cells derived from human exfoliated deciduous teeth (SHED) exhibit neurotrophic and immunomodulatory properties with potential translational relevance in inflammatory brain conditions."
• Jun Combined metformin and Taurine attenuate age-related bone loss. (Molecular biology reports, 2026, PMID 42364025): "Age-related bone loss is closely associated with functional decline and exhaustion of bone marrow mesenchymal stem cells (BMSCs)."
• Jun In vivo therapy for prenatal repair of the ovine fetal myelomeningocele model using human umbilical cord-derived mesenchymal stem cells: proof of principle. (Journal of perinatal medicine, 2026, PMID 41718757): "This study assessed the feasibility of administration human umbilical cord-derived MSCs during prenatal repair of MMC in a sheep model."
• Jun Aptamer-functionalized apoptotic vesicles ameliorate osteoarthritis via resuming mitochondria OXPHOS of chondrocytes. (Science advances, 2026, PMID 42308286): "Apoptotic vesicles (apoVs) derived from mesenchymal stem cells (MSCs) have exhibited great therapeutic promising for tissue regeneration and osteoarticular diseases."